Generic Price-Fixing: Sandoz Employee Notebook Provides Evidence For AGs' Third Suit

Complaint names 26 generic dermatologic drug manufacturers and 10 individual executives as defendants, alleging they engaged in a widespread conspiracy to artificially inflate and manipulate prices. State attorneys general say that structural and personnel changes at the companies fostered and facilitated collusion.

graphic in State AG complaint on generic price fixing
The state AGs' complaint includes a graphic showing the interlocking web of communications and relationships between executives at several of the corporate defendants and their key competitors. Each line in the graphic demonstrates that at least one phone call or text message was sent between those executives (identified by their initials) while they were competitors. For many of these executives, there were hundreds of calls and texts with competitors. • Source: State AGs' complaint

State attorneys general honed in on another segment of the generic drug industry, topical products, in their third suit alleging manufacturers and individual executives engaged in an overarching conspiracy to allocate markets and fix prices.

The allegations in the 593-page complaint, filed 10 June in the US District Court for the District of Connecticut,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Generics

More from Biosimilars & Generics